Unknown

Dataset Information

0

Biconcave Carbon Nanodisks for Enhanced Drug Accumulation and Chemo-Photothermal Tumor Therapy.


ABSTRACT: It is considered a significant challenge to construct nanocarriers that have high drug loading capacity and can overcome physiological barriers to deliver efficacious amounts of drugs to solid tumors. Here, the development of a safe, biconcave carbon nanodisk to address this challenge for treating breast cancer is reported. The nanodisk demonstrates fluorescent imaging capability, an exceedingly high loading capacity (947.8 mg g-1 , 94.78 wt%) for doxorubicin (DOX), and pH-responsive drug release. It exhibits a higher uptake rate by tumor cells and greater accumulation in tumors in a mouse model than its carbon nanosphere counterpart. In addition, the nanodisk absorbs and transforms near-infrared (NIR) light to heat, which enables simultaneous NIR-responsive drug release for chemotherapy and generation of thermal energy for tumor cell destruction. Notably, this NIR-activated dual therapy demonstrates a near complete suppression of tumor growth in a mouse model of triple-negative breast cancer when DOX-loaded nanodisks are administered systemically.

SUBMITTER: Mu Q 

PROVIDER: S-EPMC6483846 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Biconcave Carbon Nanodisks for Enhanced Drug Accumulation and Chemo-Photothermal Tumor Therapy.

Mu Qingxin Q   Wang Hui H   Gu Xinyu X   Stephen Zachary R ZR   Yen Charles C   Chang Fei-Chien FC   Dayringer Christopher J CJ   Zhang Miqin M  

Advanced healthcare materials 20190311 8


It is considered a significant challenge to construct nanocarriers that have high drug loading capacity and can overcome physiological barriers to deliver efficacious amounts of drugs to solid tumors. Here, the development of a safe, biconcave carbon nanodisk to address this challenge for treating breast cancer is reported. The nanodisk demonstrates fluorescent imaging capability, an exceedingly high loading capacity (947.8 mg g<sup>-1</sup> , 94.78 wt%) for doxorubicin (DOX), and pH-responsive  ...[more]

Similar Datasets

| S-EPMC7487365 | biostudies-literature
| S-EPMC6542907 | biostudies-other
| S-EPMC6177379 | biostudies-literature
| S-EPMC8879672 | biostudies-literature
| S-EPMC5852008 | biostudies-other
| S-EPMC5118599 | biostudies-literature
| S-EPMC6857040 | biostudies-literature
| S-EPMC7667678 | biostudies-literature
| S-EPMC7408621 | biostudies-literature
| S-EPMC3767113 | biostudies-literature